Amivantamab is a bi-specific monoclonal antibody targeting either EGFR or MET approved for patients with advanced metastatic NSCLC [146].Regardless of the progressions in MET targeting strategies and promising results, the tumor heterogeneity and selecting an appropriate population of patients benefiting from targeted therapy is challenging [147]. Here, MET is linked to neoplasm.